Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology

Schlieren (Zurich), Switzerland, February 11, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal...

read more

Molecular Partners reports key financials for FY 2018 and corporate highlights for Q4 2018: Company positioned for growth following positive phase 3 abicipar data and validation of DARPin® platform through Amgen collaboration

Zurich-Schlieren, Switzerland, February 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for...

read more


Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND OAKS, Calif.– (Dec. 19, 2018) – Molecular Partners AG (SIX: MOLN), a clinical-stage...

read more